#China #ALS #RAG-17 #Ractigen #Nantong

Ractigen Therapeutics Completes Enrollment in Phase II Trial of RAG-17

Ractigen Therapeutics, a pioneering company in RNA therapeutics, has recently announced a significant milestone in its clinical journey. The company has completed the enrollment of patients and administered the first doses in its Phase II clinical trial for RAG-17, an investigational RNA therapy aimed at addressing superoxide dismutase 1 (SOD1) mutations in amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease.

Trial Overview

The Phase II trial, identified by the registration number NCT06556394, is effectively structured as a randomized, double-blind, placebo-controlled study that evaluates the safety and efficacy of RAG-17 through multiple ascending doses. This trial is critical, as it has the potential to showcase the therapy's ability to halt or slow disease progression in patients with SOD1 mutations. The enrolled patients receive repeated intrathecal injections of the RAG-17 treatment.

From the first patient’s dosing on January 13, 2026, the trial has progressed swiftly, culminating in the completion of participant enrollment across five prominent sites in China. The rapid advancement highlights the enthusiastic engagement of healthcare professionals and patients alike within the SOD1-ALS community. Moreover, it showcases Ractigen’s operational talents amid the complexities of clinical trials.

Strength of the Clinical Team

Dr. Long-Cheng Li, M.D., the Founder and CEO of Ractigen, expressed pride in reaching this pivotal point. He emphasized the accelerated regulatory pathway the company aims to pursue, which indicates their commitment to bringing this transformative treatment to the ALS patient population. Ractigen’s earlier Phase I trials demonstrated promising results, showing significant suppression of the SOD1 protein and notable reductions in neurofilament light chains in plasma, which reinforces the potential of RAG-17.

RAG-17 Technology

RAG-17 stands out as an investigational siRNA (small interfering RNA) therapeutic candidate developed through Ractigen’s proprietary SCAD™ (Smart Chemistry-Aided Delivery) technology. This innovative platform allows the targeted silencing of mRNA that encodes the harmful SOD1 protein. SOD1 mutations are responsible for approximately 10-20% of familial ALS cases, presenting a critical target for therapeutic intervention.

The emergence of ALS poses a significant challenge to healthcare due to its progressive nature, often leading to muscle weakness, paralysis, and death within three to five years post-diagnosis. Thus, RAG-17 aims to tackle the unmet needs for effective therapies in the ALS landscape.

Regulatory Support

RAG-17 has secured Orphan Drug Designation from the U.S. FDA, signifying its potential to provide a meaningful therapeutic option for individuals with rare diseases. Additionally, the therapy is part of the CARE Program, which is designed to facilitate the expedited development of treatments for rare conditions.

Looking Ahead

As Ractigen Therapeutics prepares to enter the critical evaluation phase, the company will continue to accumulate safety, biomarker, and functional data ahead of key regulatory interactions. The engagement with regulatory authorities is part of Ractigen's strategy to offer RAG-17 to SOD1-ALS patients as swiftly as possible.

In conclusion, Ractigen Therapeutics is making strides in the fight against ALS with their RAG-17 clinical trial, reflecting the company's dedication to innovative RNA therapeutic solutions. Stakeholders, including patients, families, and the medical community, remain hopeful for the advancements that RAG-17 could bring.

For more updates on this clinical trial and future developments in RNA therapeutics, visit Ractigen's official website at www.ractigen.com.